Venus Medtech (Hangzhou) Management
Management criteria checks 1/4
Venus Medtech (Hangzhou)'s CEO ist Lin Haosheng Lim , ernannt in Dec 2016, hat eine Amtszeit von 7.08 Jahren. Die jährliche Gesamtvergütung beträgt CN¥1.26M , bestehend aus 85.4% Gehalt und 14.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.72% der Aktien des Unternehmens, im Wert von HK$17.67M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.8 Jahre bzw. 4 Jahre.
Key information
Lin Haosheng Lim
Chief executive officer
CN¥1.3m
Total compensation
CEO salary percentage | 85.4% |
CEO tenure | 7.2yrs |
CEO ownership | 0.7% |
Management average tenure | 1.9yrs |
Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?
Oct 05Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?
May 29What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You
May 11Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook
Apr 07Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?
Oct 12Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates
Sep 04We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate
Jul 28Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth
Mar 29Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?
Jan 09Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation
Dec 01We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow
Aug 16A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)
Jul 12Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth
Apr 26Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%
Apr 05Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate
Mar 07What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?
Feb 14Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner
Jan 19Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?
Dec 29Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?
Dec 29Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?
Dec 08CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2023 | n/a | n/a | -CN¥1b |
Mar 31 2023 | n/a | n/a | -CN¥1b |
Dec 31 2022 | CN¥1m | CN¥1m | -CN¥1b |
Sep 30 2022 | n/a | n/a | -CN¥759m |
Jun 30 2022 | n/a | n/a | -CN¥461m |
Mar 31 2022 | n/a | n/a | -CN¥417m |
Dec 31 2021 | CN¥1m | CN¥694k | -CN¥374m |
Vergütung im Vergleich zum Markt: Lin HaoshengDie Gesamtvergütung ($USD176.08K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD424.65K).
Entschädigung vs. Einkommen: Lin HaoshengDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
CEO
Lin Haosheng Lim (49 yo)
7.2yrs
Tenure
CN¥1,263,000
Compensation
Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
GM, COO & CTO | 7.2yrs | CN¥1.26m | 0.72% CN¥ 17.7m | |
Chief Financial Officer | less than a year | no data | no data | |
Director of Sales | 1.9yrs | no data | no data | |
Head of U.S. Operations | 4.6yrs | no data | no data | |
Head of Venus Global Heart Valve Innovation Center | 1.9yrs | no data | no data | |
Senior Vice President of Sales Europe | 1.9yrs | no data | no data | |
Executive Director | 1.1yrs | no data | no data | |
Executive Director | less than a year | no data | 0.0084% CN¥ 208.0k | |
Company Secretary | 3.1yrs | no data | no data |
1.9yrs
Average Tenure
49yo
Average Age
Erfahrenes Management: 2500Das Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Director | 1.1yrs | no data | no data | |
Executive Director | less than a year | no data | 0.0084% CN¥ 208.0k | |
Member of Advisory Board | no data | no data | no data | |
Member of Global Advisory Board | 4.1yrs | no data | no data | |
Independent Non-Executive Director | 5.3yrs | CN¥423.00k | no data | |
Independent Non-Executive Director | 4.6yrs | CN¥335.00k | no data | |
Shareholders Representative Supervisor | 5.3yrs | no data | no data | |
Member of Global Advisory Board | 4.1yrs | no data | no data | |
Employee Representative Supervisor | 1.5yrs | no data | no data | |
Non-Executive Director | 1.1yrs | no data | no data | |
Shareholders Representative Supervisor | 1.8yrs | no data | no data |
2.9yrs
Average Tenure
48yo
Average Age
Erfahrener Vorstand: 2500Die Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.